with HIV, including amplification of mRNA from T cells with primers specific to each TCR-VB to detect the presence or absence of each TCR-VB in a sample and primers for use in Such amplification assays are disclosed. The invention also provides assays of antibody-containing fluids of a person infected with HIV to determine the immunodefi ciency where the fluid is Suspected to contain an antibody having a paratope Specific to an epitope on a TCR-VB. The invention also provides a binding agent Specific to a paratope where the paratope is specific to an epitope on a TCR-VB. The invention also provides a method of assay of the fluids of a person infected with HIV to determine the immunodeficiency of the person which utilizes a binding agent specific to complexes containing anti-TCR-VB anti body bound to TCR-VB. The invention also provides a method of treatment of a person infected with HIV to attenuate or avert immunodeficiency which utilize a binding agent that is homologous with an epitope on TCR-VB. The invention also provides a method of treatment of a perSon infected with HIV to attenuate or avert immunodeficiency which involves removing an antibody capable of binding to an epitope on TCR-VB from the blood of a person infected with HIV. Finally, the invention provides a method of vaccination of a perSon infected or at risk for infection with HIV which raises antiidiotypic antibodies specific to free antibodies containing a paratope specific to an epitope on a TCR-VB. The present invention involves a method of assay of CD4+ T cells of a person infected with HIV to determine the immunodeficiency of the perSon. More specifically, the invention relates to a method of assay for the extent of depletion of Subpopulations of CD4+ T cells which express specific chains of the T cell receptor. The invention also involves additional assays, products, and methods of vacci nation related to the above.
Description of Background Art
The importance of T cell counts in HIV infected indi viduals has already been recognized. Currently, the National
Institute of Allergies and Infectious Diseases (NIAID) has
recommended that the CD4+ T cell counts in HIV-infected patients be determined two to four times per year. Healthy individuals normally have 800-1000 CD4+ cells/ul of blood. NIAID recommends that AZT treatment begin when CD4 levels drops to 500 CD4+ cells/ul and that when levels drop below 200 CD4+ cells/ul that AZT be discontinued and pentamidine therapy be undertaken. CD4+ cell counts are currently performed using flow cytometry. FDA approval has recently been Sought for a method of counting CD4+ cells by Solubilizing CD4 receptors and quantifying by means of a microtiter calorimetric immunoassay.
The cause of T cell depletion in HIV infected individuals has remained a mystery, however. It is unlikely that T cell depletion is a direct result of HIV infection. Although HIV is known to infect CD4+ T cells by binding to the surface protein, only a fraction of CD4+ T cells, around 1 in 10000 are actually infected with the virus. A number of theories have been proposed to explain the depletion phenomenon but none have been proven or disproved.
One theory is that HIV requires the presence of another pathogen to deplete immune cell populations. The Second pathogen may be opportunistic and depress the immune System simply by its presence. The Second pathogen may also work as a "co-factor" working in concert with the HIV Virus to directly Suppress T cell populations. Mycoplasmas have been proposed as one candidate for co-factor pathogen Status. A Second theory is that HIV triggers an autoimmune reaction that destroys immune cells. There is no agreement as to which of the possible markers on immune cells provides the binding site for the autoimmune antibodies. One group has proposed that antibodies to HIV envelope protein (gp120) could recognize and bind to the major histocompatibility (MHC) proteins. These anti-MHC anti bodies would then cause the depletion of the T cells.
A third theory is that HIV-infected T cells fuse with uninfected cells to produce Syncytia consisting of non functioning cells. Thus, a single HIV-infected cell could bring about the demise of many non-infected T cells. The observation of Syncytia formation was made in vitro, and no in vivo results have yet been published to substantiate this hypothesis.
Finally, Some researchers have proposed that T cell deple tion is caused by a HIV protein acting as a Superantigen. Normally, when antigen is presented to a T cell, interaction 2 of the alpha and beta chains of the T cell receptor with antigen is required for T cell activation. Superantigens interact only with the beta chain and are able to bypass the requirement of alpha chain interaction. By removing the alpha chain requirement, Superantigens are able to activate a much larger proportion of the T cell Subpopulation. Furthermore, T cells Stimulated by Superantigens eventually lose their ability to respond to antigens and undergo a programmed cell death known as apoptosis.
There is no agreement as to which HIV protein might have Superantigen properties and, indeed, there has been no direct proof of Superantigen involvement in T cell depletion. Some researchers have proposed that HIV gp120 may be the Superantigen. Others have proposed that the nef gene pro duced by an open reading frame at the 3' end of the HIV genome may be the Superantigen.
It is an object of the invention to delineate the pattern of T cell depletion in HIV infected individuals in order to develop effective intervention therapies to slow or halt T cell depletion and to more effectively time preventive treatment for opportunistic diseases.
SUMMARY OF THE INVENTION
The invention relates to a method of assay of CD4+ T cells of a person infected with HIV, preferably HIV-1, to determine the immunodeficiency of the person. This method involves measuring the extent of depletion of a CD4+ T cell subtype. The subtype is defined by the expression of a particular beta chain of the T cell receptor, having a constant region and a variable region (the variable region hereinafter designated TCR-V8 or VB). The selection of the TCR-V8s may be any of the TCR-VBs, including TCR-VB14, TCR VB15, TCR-VB16, TCR-VB17, TCR-VB18, TCR-VB19, or TCR-VB20.
In one embodiment of the foregoing assay a Sample from the HIV infected person is isolated. The sample is prepared for contact with a binding agent Specific to an analog of TCR-VB. The analog may be TCR-VB, a fragment of TCR-VB, mRNA encoding TCR-VB, mRNA encoding a fragment of TCR-VB, genomic DNA encoding TCR-VB, genomic DNA encoding a fragment of TCR-VB, cDNA encoding TCR-VB, or cDNA encoding a fragment of TCR VB. The prepared Sample is contacted with the binding agent under conditions Suitable for binding of the binding agent and the analog. The extent of the binding is determined and a correlation is made to the extent of the depletion.
The binding agent in the foregoing assay may be an antibody, a fragment of an antibody, a binding receptor or a binding receptor fragment. The binding agent may also be a nucleic acid probe where the analog is in the form of mRNA, genomic DNA or cDNA.
Another embodiment of the foregoing assay involves isolating a sample from the HIV infected person. The sample is then prepared for contact with a first primer and a Second primer. The first primer is Substantially homologous to genomic DNA, mRNA or cDNA encoding a portion of the constant region of the TCR-3 chain and the Second primer is substantially homologous to genomic DNA, mRNA or cDNA encoding a portion of the variable region of the TCR-3 chain. The prepared sample is contacted with the first and Second primers and amplification enzymes under con ditions Suitable for amplification of the analog. The extent of the amplification is determined and a correlation is made to the extent of the depletion.
The first primer may be GTGCACCTCCTTCCCATT (SEQ ID NO: 1) and the second primer may be any one of The invention further relates to a method of assay of an antibody-containing fluid of a person infected with HIV to determine the immunodeficiency of the person. The method involves isolating a Sample from the HIV-infected person, where the Sample is Suspected to contain an antibody having a paratope specific to the variable region of a TCR-3 chain (TCR-VB). The sample is prepared for contact with a binding agent Specific to the paratope of the antibody. The prepared Sample is contacted with the binding agent under conditions suitable for binding of the antibody with the binding agent. The extent of the binding is determined and a correlation is made to the extent of the depletion. In a preferred embodiment of the foregoing assay, the paratope of the antibody may be specific to an epitope on any one of the following: Ser-Ala-Val-Ile-Ser-Gln-Lys-Pro-Ser-Arg The paratope may alternatively be specific to an epitope on a TCR-VB which is one of the following: TCR-VB14, TCR-VB15, TCR-VB16, TCR-VB17, TCR-VB18, TCR VB19, and TCR-VB20. The paratope of the antibody, in addition to the above Specificities, may also be specific to an epitope on gp120 of HIV. In another embodiment of the foregoing assay, the binding agent may be an antibody, an antibody fragment, a binding receptor, or a polypeptide containing fewer than 100 amino acids.
The invention further relates to a binding agent Specific to a paratope on a human antibody. The paratope on the antibody is specific to an epitope on a TCR-VB. The binding agent may be an antibody or an antibody fragment. The antibody may be a binding receptor or a binding receptor fragment. The binding agent may also be described as a polypeptide containing fewer than 100 amino acids. In a preferred embodiment, the epitope on the binding agent may be on an amino acid Sequence which is one of the following: Ser-Ala-Val-Ile-Ser-Gln-Lys-Pro-Ser-Arg-Asp-Ile-Cys Gln-Arg-Gly-Thr-Ser-Leu-Thr (SEQ ID NO: 28); Gln-Leu Gln-Glu-Thr-Glu-Asn-His-Lys-Lys-Arg-Phe-Ser-Ser-Gln Cys-Pro; Gln-Asn-Leu-Ser-Ala-Ser-Arg-Pro-Gln-Asp-Arg Gln-Phe-Ile-Leu-Ser-Ser-Lys; Asp-Gly-Tyr-Ser-Val-Ser Arg-Ser-Lys-Thr-Glu-Asp-Phe-Leu-Leu, Pro-Arg-ASn-Arg Ile-Thr-Lys-Ile-Gly-Lys-Arg-Ile-Met-Leu-Glu-Cys, or Pro Arg-His-Leu-Val-Arg-Arg-Arg-Gly-Gln-Glu-Ala-Arg-Leu Arg-CyS.
The invention further relates to a method of assay of the fluids of a person infected with HIV to determine the immunodeficiency of the person. The method involves iso lating a sample from the HIV infected person, where the Sample is Suspected to contain an antibody having a paratope specific to an epitope on a TCR-VB and being bound to the TCR-VB by the paratope to form an antibody-TCR-VB pair. The Sample is prepared for contact with a binding agent which selectively binds to the antibody-TCR-VB pair. The binding agent does not bind to the antibody when the antibody is not bound to TCR-VB and the binding agent does not bind to the TCR-VB when the antibody is not bound to TCR-VB. The prepared sample is contacted with the binding agent under conditions Suitable for binding of the binding agent to any TCR-VB-pair. The extent of the binding is determined and a correlation is made to the presence or amount of such antibody-TCR-VB pairing.
The invention further relates to a method of treatment of a person infected with HIV to attenuate or avert immuno deficiency in the person infected with HIV. The method involves inoculating the person infected with HIV with a binding agent which is Substantially homologous with an epitope on a TCR-VB and which is reactive with a paratope on a free antibody in the person's blood, where the paratope is specific to the epitope on the TCR-VB. The binding agent may be a polypeptide, a binding receptor or a binding receptor fragment. The binding agent may also be an anti idiotypic antibody or an antiidiotypic antibody fragment. An antiidiotypic antibody is specific to the paratope of another antibody (ie. binding of the antiidiotypic antibody prevents the other antibody from being able to bind to an epitope). S Antiidiotypic antibody fragments useful in the invention are those fragments of antiidiotypic antibodies which possess the ability to prevent an antibody from being able to bind to an epitope.
The invention further relates to another method of treat ment of a person infected with HIV to attenuate or avert immunodeficiency. The method involves removing blood from the person infected with HIV; removing antibody from the blood of the perSon, the antibody having a paratope Specific to an epitope present on TCR-VB and reintroducing the blood into the person.
The invention finally relates to a method of vaccination of a person infected with HIV or a person at risk for infection with HIV in order to attenuate or avert immunodeficiency. The method involves inoculating the perSon with an immu nogenic Substance capable of raising antiidiotypic antibod ies in the perSon. The antiidiotypic antibodies are specific to free antibodies containing a paratope Specific to an epitope on a TCR-VB. In one embodiment of the foregoing assay a Sample from the HIV infected person is isolated. The sample is prepared for contact with a binding agent specific to a TCR-VB subtype which may be the TCR-VB protein, a fragment of the TCR-VB protein, mRNA encoding the TCR-VB, mRNA encoding a fragment of the TCR-VB, genomic DNA encod ing TCR-VB, genomic DNA encoding a fragment of TCR VB, cDNA encoding TCR-VB, or cDNA encoding a frag ment of TCR-VB. The sample is preferably blood, although any fluid containing a representative population of CD4+ T cells will work with the method. The prepared sample is contacted with the binding agent under conditions Suitable for binding of the binding agent and the analog. The extent of the binding is determined and a correlation is made to the extent of the depletion.
Where the analog is the TCR-VB protein or a fragment of the TCR-VB protein the binding agent in the foregoing assay may be an antibody, a fragment of an antibody, a binding receptor, or a binding receptor fragment which Selectively recognize and bind to portions of the TCR-VB protein. If a fragment of an antibody is used as the binding agent, the only requirement of the fragment is that the fragment is able to specifically recognize and bind to any one TCR-VB Subtype. A receptor may be any non-immunoglobulin pro tein which is ordinarily found on the Surface of any cell type. The receptor may be prepared by any conventional means which involves freeing the receptor from the cell membrane and isolating the receptor in a Substantially pure form. Alternatively, the receptor may be prepared by recombinant DNA methods, including producing the receptor in a trans formed host and isolating the receptor in a Substantially pure form. The analog may be the TCR-VB protein which is present on intact T cells. In this case, flow cytometry may be used to determine the extent to the binding of the analog. The analog may also be the TCR-VB protein or a fragment of the TCR-VB protein which has been released from T cells by The binding agent may also be a nucleic acid probe where the analog is in the form of mRNA, genomic DNA or cDNA. The Sequence of the probe is Substantially homologous to the sequence of any one TCR-VB subtype and will prefer entially hybridize to any nucleic acid encoding the same type of specific TCR-VB under appropriate hybridization conditions. Methods of predicting appropriate hybridization conditions or determining Such conditions are known in the art. The probe may be labelled by any conventional method, including labelling with P-or S-tagged nucleotides at one end or throughout the probe, labelling with biotin tagged nucleotides, and chemiluminescent labelling. Alternatively, a Second probe may be utilized in a Sandwich or other format to detect the binding of this above probe.
Where the analog is mRNA or cDNA which is prepared from the total RNA or mRNA present in a sample, there is 7 no need to isolate Subpopulations of cells from the Sample. However, it is preferable to isolate peripheral blood mono nuclear cells and isolate total RNA from these cells prior to preparing cDNA. Where the analog is genomic DNA, any cell which does not express a specific TCR-VB may be removed from the sample so that the genomic DNA is indicative of the presence of the specific TCR-VB subtype.
Another embodiment of the foregoing assay involves isolating a Sample from the HIV infected perSon and pre paring the Sample for contact with a first primer and a Second primer. A preferred method of preparation is performed by isolation of peripheral blood mononuclear cells, isolation of total RNA from the cells and first strand synthesis of cDNA. The primers are oligonucleotides which can be prepared on commercially available Synthesis machines or ordered from a company providing Such Services. The oligonucleotides are preferably DNA, although any nucleic acid may be used provided that the primer is able to hybridize to the nucleic acid analog and is also able to function in amplification reactions.
The first primer is Substantially homologous to genomic DNA, mRNA or cDNA encoding a portion of the constant region of the TCR-3 chain and the second primer is sub stantially homologous to genomic DNA, mRNA or cDNA encoding a portion of the variable region of the TCR-f chain. The Second primer must be capable of Selectively binding to a Sequence within any TCR-VB coding Sequence in order to insure that only nucleic acids encoding TCR-VB of the desired Subtype are amplified in the following StepS. The prepared Sample is contacted with the first and Second primerS and amplification enzymes under conditions Suit able for amplification of the analog. In a preferred embodiment, amplification is performed using the poly merase chain reaction (PCR) utilizing VB-and CB-specific primers shown in Table II . Other amplification techniques which use the analog as a template and are capable of reproducing a portion of the analog or its corresponding opposite Strand, Such as the ligase chain reaction, may also be employed. The extent of the amplification is determined and a correlation is made to the extent of the depletion. The extent of amplification may also be determined using a DNA Enzyme Immunoassay (DEIA) kit available from Sorin Biomedica S.p.A. (Saluggia (VC), Italy)
The invention further relates to a method of assay of an antibody-containing fluid of a person infected with HIV to determine the immunodeficiency of the perSon, where the Sample is Suspected to contain an antibody having a paratope specific to a TCR-VB subtype. A paratope is defined as that portion of an antibody which enables the antibody to rec ognize and Selectively bind to an epitope. The Sample is prepared for contact with a binding agent Specific to the paratope of the antibody. The prepared Sample is contacted with the binding agent under conditions Suitable for binding of the antibody with the binding agent. The extent of the binding is determined and a correlation is made to the extent of the depletion. The extent of the binding can be determined by conventional methods, as indicated above.
In another embodiment of the foregoing assay, the paratope of the antibody may be specific to an epitope which is present on a peptide and the peptide is one of the following: Ser-Ala-Val-Ile-Ser-Gln-Lys-Pro-Ser-Arg-Asp Ile-Cys-Gln-Arg-Gly-Thr-Ser-Leu-Thr; Gln-Leu-Gln-Glu Thr-Glu-Asn-His-Lys-Lys-Arg-Phe-Ser-Ser-Gln-Cys-Pro; Gln-Asn-Leu-Ser-Ala-Ser-Arg-Pro-Gln-Asp-Arg-Gln-Phe Ile-Leu-Ser-Ser-Lys; Asp-Gly-Tyr-Ser-Val-Ser-Arg-Ser Lys-Thr-Glu-Asp-Phe-Leu-Leu, Pro-Arg-Asn-Arg-Ile-Thr Lys-Ile-Gly-Lys-Arg-Ile-Met-Leu-Glu-Cys, or Pro-Arg The paratope may also be specific to an epitope on a TCR-VB with, which is one of the following: TCR-VB14, TCR-VB15, TCR-VB16, TCR-VB17, TCR-VB18, TCR VB19, and TCR-VB20. The paratope of the antibody may also be specific to an epitope on gp120 of HIV.
In another embodiment of the foregoing assay, the binding agent may be an antibody, an antibody fragment, a binding receptor, a binding receptor fragment, or a polypeptide containing fewer than 100 amino acids where the polypep tide is capable of recognizing and Selectively binding to the paratope.
The invention further relates to a binding agent Specific to a paratope on a human antibody. The paratope on the antibody is specific to an epitope on a TCR-VB. The binding agent may itself be an antibody or an antibody fragment. The binding agent may be a binding receptor or a binding receptor fragment. The binding agent may also be described as a polypeptide containing fewer than 100 amino acids. The epitope on the binding agent may be on an amino acid sequence which is one of the following: Ser-Ala-Val-Ile Ser-Gln-Lys-Pro-Ser-Arg-Asp-Ile-Cys-Gln-Arg-Gly-Thr Ser-Leu-Thr, Gln-Leu-Gln-Glu-Thr-Glu-Asn-His-Lys-Lys Arg-Phe-Ser-Ser-Gln-Cys-Pro; Gln-Asn-Leu-Ser-Ala-Ser Arg-Pro-Gln-Asp-Arg-Gln-Phe-Ile-Leu-Ser-Ser-Lys; Asp Gly-Tyr-Ser-Val-Ser-Arg-Ser-Lys-Thr-Glu-Asp-Phe-Leu Leu, Pro-Arg-ASn-Arg-Ile-Thr-Lys-Ile-Gly-Lys-Arg-Ile Met-Leu-Glu-Cys, or Pro-Arg-His-Leu-Val-Arg-Arg-Arg Gly-Gln-Glu-Ala-Arg-Leu-Arg-CyS.
The invention further relates to another method of assay of the fluids of a person infected with HIV to determine the immunodeficiency of the person. The method involves iso lating a sample of a fluid from the HIV infected person where the Sample is Suspected to contain an antibody having a paratope Specific to an epitope on a TCR-VB and being bound to the TCR-VB by the paratope to form an antibody TCR-VB pair. The sample is preferably blood or a blood fraction, although any bodily fluid which may contain an antibody-TCR-VB pair may be used. The sample is prepared for contact with a binding agent which Selectively binds to the antibody-TCR-VB pair. The binding agent does not bind to the antibody when the antibody is not bound to TCR-VB (ie. when the antibody is not a component of an antibody TCR-VB pair) and the binding agent does not bind to the TCR-V8 when the antibody is not bound to TCR-VB (ie. In many of the foregoing assays a Sample is prepared for binding with a binding agent. In the case where blood is used, it may be helpful to convert the blood to serum. In Some cases further processing of the Serum (e.g. by centrifu gation to isolate certain cell types) may be necessary. Steps Total RNA was prepared from about 0.5x107 to 1x107
PBMCs by the guanidine isothiocyanate-phenol-chloroform extraction method. PBMCs were washed 3 times with Phos phate Buffered Saline (PBS) and resuspended in 1 ml of a Solution containing 4M guanidine isothiocyanate; 25 mM sodium citrate, pH 7.0; 0.5% sarcosyl; and 0.1M B-mercaptoethanol. 0.1 ml of 2M sodium acetate, pH 4.0; 1 ml of phenol and 0.2 ml of chloroform-isoamyl alcohol mixture (1:49) were sequentially added to lysed cells and the resulting preparation was vigorously shaken, cooled on ice for 15 min and centrifuged at 10,000 g for 20 min at 4 C.
The RNA, present in the aqueous phase, was mixed with 1 ml of isopropanol and left for 1 h at -20°C. The RNA pellet, resulted from a further centrifugation, was dissolved in guanidine isothiocyanate Solution and precipitated with iso propanol at -20° C. for 1 h. The RNA pellet was resus pended in 75% ethanol, vacuum dried and dissolved in 50 ul of HO, 0.1% diethylpyrocarbonate. Two ug of the RNA preparation was used to Synthesize the first strand of the complementary DNA (cDNA) with a Riboclone cDNA Synthesis System, Promega Corp.
(Madison, Wis.), using the instructions from the manufac turer.
For the analysis of the expression of human T cell receptor (TCR) Vol. and VB repertoire, 19 Voi, 22 VB, 2 Co. and 2 CB Specific oligonucleotides, one of which was chosen to match a common Sequence near to the 5' ends of the CB1 and CB2 genes, were prepared. The Sequences of the oligonucleotides, reported in Table II , were obtained from previously published reports and were Selected to contain roughly the same G+C content as the other primerS. 16.6 mM (NHA)SO; 10 mM f-mercaptoethanol; 6.7 BM EDTA; 1.5 mM MgCl, and 170 ug/ml of BSA. The final reaction volume was brought to 100 ul with double distilled HO and the mixture was overlaid with 50 All of mineral oil, heated in water bath at 95 C. for 5 min and cooled rapidly on ice, in order to denature the DNA/RNA complexes. The reaction was taken through 40 cycles in a thermal automatic cycler (Perkin-Elmer Thermal Cycler; Norwalk, Conn.), with each cycle consisting of 94° C. for 1 min (denaturation Step), 55 C. for 1 min (annealing step), 72° C. for 1.5 min (elongation step). The assay for the presence or absence of each amplifica tion product was carried out using an assay containing an antibody specific to double stranded DNA (available as DEIA assay by Sorin Biomedica S.p.A., Saluggia(VC), Italy). The expression of each V gene transcript was opera tionally defined by an optical density value obtained with the DEIA test, performed using a CB or a CC. Specific capture probe, mapping to a region internal to the amplified cDNA. The test is based on a monoclonal antibody that recognizes double stranded, but not single stranded DNA. Thus, the antibody can only react with the solid phase if the amplified product is complementary to the immobilized probe. The sensitivity and the specificity of the DEIA assay is similar to conventional Southern blot.
The CCNH and CBNH oligonucleotides used as capture probes (for Sequences, see Table II) The amplification mixtures from Example 3 were dena tured on a heat block for 10 min at 100° C. and then quickly cooled on ice. Twenty ul of the amplification product, diluted 5 times in hybridization solution (1x SSC, 2x
Denhardt's solution, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA), were added to the coated wells and incubated for 1 h at 50 C. After 5 washes with washing solution, each well received 100 ul of a 1/1000 dilution in PBS-10% Fetal Calf Serum (FCS) of a standard preparation of the 27 14-D9 mAb, specific to double stranded DNA.
After 2 h incubation at 37 C. and 5 washes with washing solution, the bound antibody was revealed with 100 ul of HRP-labeled rabbit anti-mouse IgG antibody (ICN Biochemical, High Wycombe, Bucks, England) diluted 1/20,000 in PBS10% FCS. Following 1 h incubation at room temperature and 5 washes, the wells received 100 ul of the chromogen/substrate solution (0.1M citrate buffer, pH 5, containing phenylenediamine hydrochloride and 10 ul of H2O) and the calorimetric reaction was allowed to develop for 30 min at room temperature in the dark. After blocking with 200 ul of 1N sulfuric acid, the net absorbance was read in a spectrophotometer at 450 nm.
The expression of most of the known TCR Vol. and VfB genes was analyzed by amplification of mRNA from PBMCs obtained from 6 patients affected by AIDS and from 6 normal healthy individuals. Total RNA was separated from each Sample immediately after collection and, at the time of analysis, was reverse transcribed in cDNA, as described in Example 1. Aliquots of cDNA were amplified, as described in Example 3, with each of the 22 5' VB-specific sense primerS and a 3' CC-Specific antisense primer or with each of the 195' VC. specific sense primers and a 3' Co-specific antisense primer. Altogether, these primers are expected to cover most of the sequenced human TCRVO. and VB genes.
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Although the oligonucleotides specific to VB21-24 were not used in the current example, one could also use these oligonucleotides as primers to expand the Scope of the analysis.
The comparative analysis of the VB repertoire in AIDS patients and in normal controls revealed the existence of important differences in the number of the VB genes expressed by the two groups FIG. 1 . Expression of the TCR-VB genes in T cells from AIDS patients (O) and from normal controls(o) is shown in the figure. The results are expressed as absorbance at 450 nm from the DEIA test. The cut-off value was 0.20 and represents the mean value of 10 negative controls +3 SD. The VB14, VB15, VB16 and VB18 Sequences could not be detected in any of the cDNAS derived from lymphocytes of HIV+ patients. Similarly, VB17, VB19 and VB20 were found to be expressed in only one of these cDNAs. All other VB genes analyzed were randomly represented in HIV+ patient cells.
The results reported in FIG.2 demonstrate that there were no major differences between the Vol. repertoires of normal individuals and of HIV+ patients. Expression of the TCR VB genes in T cells from AIDS patients (O) and from normal controls(o) is shown in the figure, the results are expressed as absorbance at 450 nm from the DEIA test. The cut-off value was 0.20 and represents the mean value of 10 negative controls +3 SD. Most of the Vol. genes were expressed in all Samples and there was no evidence of important genomic or Somatic deletions. Although the results are only qualitative, due to possible variations in the efficiency of the amplification reactions, it appeared that the relative abundance of the 19 VC. transcripts analyzed was highly variable in both group of Samples. These variations are probably correlated to the positive and negative Selec tions processed that occur in the periphery of the immune System.
Example 5
Analysis of the VB repertoire by Southern Blot Hybridization VB expression in T cells from individual AIDS patients (group 1 of Table I), and from one healthy control also of Table I , was also analyzed by Southern blot hybridization with a Plabeled CB-specific probe. After amplification, the layer of mineral oil was removed and aliquots (10 ul) of each amplification reaction were analyzed by electrophoresis in 1% agarose gels. Bands were visualized by ethidium bro mide Staining and photographed at 302 nm. The expected size of the amplification products obtained was 129 base pairs (bp) for Vol.-Co. products and 330 bp for VB-CB products.
Electrophoresed amplified DNA was transferred to
Hybond N nylon blotting membrane (Amersham, Amersham, UK), following the manufacturer's instructions. Filters were incubated for 2 h at 65 C. in prehybridization solution containing 5x SSC (1x SSC: 0.15M NaCl, 0.015M sodium citrate), 5x Denhardt's solution (1x Denhardt's: 0.02% polyvinyl pyrrolidone, 0.02% Ficoll, 0.02% BSA), 0.1% SDS, 100 ug/ml salmon sperm DNA and then hybrid ized overnight at 42°C. with P-labeled CB5' specific probe at 1x10 cpm/ml of hybridization solution. The membrane 14 TCR-VB transcripts obtained with T cell from a normal control. The experiment was carried out as described, using the CBNH oligonucleotide shown in Table II Table I ).
T cells from the control expressed all the VB genes, but there were considerable differences in the level of the individual transcripts. In this sample VB15, VB16 and VB18 were the least expressed, while VB5.1 and VB13.1 were the most abundant. The VB repertoire of the AIDS patients was, in general, more restricted as compared to the normal control, but the degree of this restriction varied considerably among the different samples. Patient B expressed only VB1, VB5.2 and VB6; all other transcripts were either absent or barely detectable. The next most compromised repertoire was the one of patient A, in which we detected only 8 of the 22 transcript tested. Patient D expressed the highest number of VB genes but, even in this case, the transcription of 8 VB Segments could not be detected. The most Striking result of this analysis was that, beside the individual variations, all Samples lacked the expression of a common Set of VB genes comprising VB14, VB15, VB16, VB17, VB18, VB19 and VB20. The only exception was patient F that expressed VB19 and extremely low levels of VB17. These results establish that HIV infection results in a severely compro mised VB repertoire in which members of particular VB families are preferentially affected.
Example 6 VB mRNA Levels and Disease Progression To study whether VB extinction correlates with the pro gression of HIV infection to AIDS, we analyzed the expres sion of VB genes in two other groups of HIV positive patients. Group A consisted of patients with Severe immune depletion (CD4<200 mmc), without the occurrence of the clinical manifestation of AIDS syndrome (CDC stage III).
Group B consisted of patients with a long history of HIV infection (>5 years) that had retained a normal immunologi cal profile (CDC stage II). The results reported in FIG. 4 show that the two groups display a distinct pattern of VB expression. The pattern of the group A (indicated by a "O'") patients strongly resembles the one seen in stage IVC1AIDS patients in which VB14, VB15, VB16, VB17, VB18, VB19 and VB20 are either not expressed or barely detectable.
Conversely, the group B (indicated by a "o") displayed a pattern of VB expression more Similar to the one of normal controls, in which most of the VB genes were randomly represented.
Example 7
Immunofluorescence Analysis of Cells Fluorescein-conjugated mAb to CD3 and CD4 (T3 FITC and T4-FITC) were purchased from Coulter Immunology, Hialeah, Fla., and the fluorescein-conjugated anti-TCR specific antibodies (anti VB5, anti-VB6, anti-VB8 and anti VB12) were purchased from T Cell Diagnostic, Inc., Cambridge, Mass. Staphylococcal enterotoxins E, B and C2 (SEE, SEB and SEC2) were purchased from Serva Feinbiochemica, GmbH & Co. Heidelberg. Peripheral blood mononuclear cells (PBMC) were pre pared from heparinized human peripheral blood Samples from clinically healthy donors as in Example 1. Cells were placed at a concentration of 2x10"/ml on petri dishes coated either with 100 ng/ml of T3 mAb or with 10 ng/ml of SEE, 50 ng/ml of SEC2 and 100 ng/mnl of SEB. The enterotoxin SEB is known to stimulate T cells positive for VB3, VB12, VB14, VB15, VB17, and VB20; SEC2 is known to stimulate T cells positive for VB12, VB13.1, VB13.2, VB14, VB15, VB17, and VB20; and SEE is known to stimulate T cells positive for VB5.1, VB6.1, VB6.2, VB6.3, VB8, and VB18. After 3 days of culturing, the activated cells were washed and incubated overnight with or without two doses (67.2 and 6.72 ng/ml) of insolubilized gp120 (Transgene, Stranbourg) in RPMI 1640 (GIBCO Laboratories, Grand Island, N.Y.) . In another series of experiments 2x10" lymphocytes were preincubated overnight with 67.2 ng/ml of gp120 and then for 4 or 5 days with SEE (10 ng/ml), SEC2 (50 ng/ml) or SEB (100 ng/ml). PBMCs from healthy individuals were first activated with the Superantigens SEB, SEC2 and SEE that selectively expand those cells bearing VB regions for which specific monoclonal antibodies are available. After 3 days of cultur ing the activated cells were washed and incubated overnight with or without various doses of insolubilized gp120. Flow cytometric analysis with fluorescein-labeled antibodies Spe cific to CD3, CD4, VB5, VB6, VB8 and VB12 revealed that preincubation with gp120 did not change the membrane expression of CD3 and CD4 (FIG. 5) , but resulted in membrane down-modulation of Some, but not all, VB Seg ments and that the phenomenon was Strictly dependent on the concentration of gp120 added to the cultures (FIG. 6) .
Different VB segments were modulated in cell samples deriving from different donors, Suggesting that polymorphic Structures may be involved in this interaction.
In a second series of experiments PBMC were first incubated overnight with or without gp120 and, after Washing, recultured for five days in the presence of SEB, SEC2, SEE. Flow cytometric analysis using fluoresceined anti-VB antibodies revealed that, in Some Samples, preincu bation with gp120 favored the expansion of those cells bearing VB6 and VB8 but not of those bearing VB5 and VB12 (FIG. 7) . Taken together, these observations suggest that only Some VB Segments may act as a co-receptor for gp120.
Example 8
Autoimmunity and TCR-VB Components A comparison of the amino acid Sequences of gp120 and the known human TCR Segments carried out in our labora tories has revealed that gp120 shares common motifs with Some VB genes. Some of these motifs map in the most potentially antigenic region of the relevant VB Segments. On Cys-Gln-Arg-Gly-Thr-Ser-Leu-Thr), VB19 (Gln-Leu-Gln Glu-Thr-Glu-Asn-His-Lys-Lys-Arg-Phe-Ser-Ser-Gln-Cys Pro) and VB20 (Gln-Asn-Leu-Ser-Ala-Ser-Arg-Pro-Gln Asp-Arg-Gln-Phe-Ile-Leu-Ser-Ser-Lys). These peptides can be found in the region of greatest peptide hydrophilicity for each of the corresponding peptides (FIG. 8) . The choice of these immunodominant epitopes of these TCRVB peptides was done with the aid of a computer program (PCGENE; Intelligenetics) using the Hopp and Wood algorithm.
Alternatively, one could construct the following Series of peptides for use in the present invention: VB12 (Asp-Gly Tyr-Ser-Val-Ser-Arg-Ser-Lys-Thr-Glu-Asp-Phe-Leu-Leu), VB15 (Pro-Arg-Asn-Arg-Ile-Thr-Lys-Ile-Gly-Lys-Arg-Ile Met-Leu-Glu-CyS), and VB18 (Pro-Arg-His-Leu-Val-Arg Arg-Arg-Gly-Gln-Glu-Ala-Arg-Leu-Arg-CyS).
The peptides were Synthetized by Solid phase peptide Synthesis now described. A polyamidic resin, functionalized with the C-terminal amino acid (0.1 med/g), was used as Solid Support. All of the amino acids were pentafluorophenyl esters preactivated and protected at the C-amino group with 9-fluorenilmethoxycarbonyl (Fmoc) and in the lateral chains according to the nature of Specific amino acid, 1-hydroxy benzothriazole (HOBT) was used as catalyst and each coupling was conducted in dimethyl formamide (DMF) with a 5 fold excess of amino acid for 2 hours. DMF was used for wash and 20% piperidine/DMF for the deprotection of the C.-amino groups. At the end of Synthesis the resin was washed Successively with DMF, glacial acetic acid, tort amylic alcohol, dietyl ether and dessicated. The peptide was cleaved from the resin with a mixture of trifluoroacetic acid (TFA) and scavengers (anisole, phenol, ethandiol (EDT)) for 2 hours at room temperature (94%TFA, 5% anisole and 1%
EDT for VB4, VP15, VB18, and VB19; 95% TFA and 5% phenol for VB12 and VB20). The resin was separated from the solution by filtration, the filtrate was evaporated and the slurry obtained was precipitated with diethyl ether. The product was repeatedly washed with diethyl ether, then dissolved in glacial acetic acid and lyophilized. The peptides were purified by RP-HPLC on a C18 column with a gradient of water and acetonitrile both containing 0.1% TFA. The composition of the peptides was controlled by amino acid analysis with phenylisothiocyanate (PITC) pre-column derivatization.
The sera of AIDS patients (CDC stage: IV) and healthy HIV-individuals were then tested for immunoreactivity against this first Series of peptides. Microtiter dishes were coated by treating with 200 ul of a 5 lug/ml peptide Solution in 0.05M carbonate buffer, pH 9.6 for one hour at 37°C. The peptide Solution was then removed and the Wells overcoated with 300 ul of 0.2% BSA in 0.1M Tris.HCl buffer, pH 7.4 for two hours at room temperature. The wells were then fixed with 300 ul of 10% saccharose, 4% PVP, 9% NaCl in water for one hour at room temperature. The fix Solution was removed and the Wells dessicated at room temperature overnight. The various sera were diluted 1/50 in PBS/10% FCS and 200 ul of the diluted sera were added to wells for one hour at 37 C. The Sera were then removed and the wells washed with "wash buffer" from ETI-Kits (Sorin Bio medica; Saluggia, Italy). Polyclonal anti-human Ig-peroxidase conjugated was diluted 1/3000 in PBS/10% FCS and 200 ul aliquots were added to the wells for one hour at 37 C. The wells were then washed three times with "wash buffer". Chromogen-substrate (100 ul, diluted 1:1 according to instructions) was added in the dark and allowed to incubate for 30 minutes at room temperature. The reaction was stopped with 0.1M Sulphuric acid. 
